Caphosol, a therapeutic option in case of cancer therapy-induced oral mucositis in children? Results from a prospective multicenter double blind randomized controlled trial

Autor: A.M. den Boer, Martine Raphael, H. Mekelenkamp, Wim J. E. Tissing, Gertjan J.L. Kaspers, Floor Abbink, W. J. W. Kollen, K. Zomer-Kooijker, B. H. W. Molmans
Přispěvatelé: Pediatric surgery, CCA - Innovative therapy, Faculteit Medische Wetenschappen/UMCG, Guided Treatment in Optimal Selected Cancer Patients (GUTS)
Jazyk: angličtina
Rok vydání: 2014
Předmět:
Zdroj: Supportive Care in Cancer, 22(1), 3-6. Springer Verlag
Supportive Care in Cancer, 22(1), 3-6
Supportive Care in Cancer, 22(1), 3-6. SPRINGER
Raphael, M F, Laheij-de Boer, A M, Kollen, W J W, Mekelenkamp, H, Abbink, F C H, Kaspers, G J L, Zomer-Kooijker, K, Molmans, B H W & Tissing, W J E 2014, ' Caphosol, a therapeutic option in case of cancer therapy-induced oral mucositis in children? Results from a prospective multicenter double blind randomized controlled trial ', Supportive Care in Cancer, vol. 22, no. 1, pp. 3-6 . https://doi.org/10.1007/s00520-013-2015-0
ISSN: 0941-4355
DOI: 10.1007/s00520-013-2015-0
Popis: In pediatric oncology, chemotherapyor radiotherapy-induced oral mucositis (OM) is accompanied by decreased oral intake, pain, analgesics use, and hospital admission [1, 2]. Moreover, OM is correlated with an increased risk of sepsis [3, 4]. Recently, Caphosol, a supersaturated CaPO4 mouth rinse, became available to prevent or treat mucositis [5]. Papas et al. demonstrated Caphosol to have a beneficial prophylactic effect in adult hematopoietic stem cell transplantation (HSCT) patients, but evidence in pediatric patients is lacking [6]. We studied whether Caphosol can be used to treat OM in a prospective randomized study.
Databáze: OpenAIRE